Philip E. Thorpe

13.0k total citations · 1 hit paper
134 papers, 10.6k citations indexed

About

Philip E. Thorpe is a scholar working on Molecular Biology, Immunology and Biotechnology. According to data from OpenAlex, Philip E. Thorpe has authored 134 papers receiving a total of 10.6k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Molecular Biology, 82 papers in Immunology and 38 papers in Biotechnology. Recurrent topics in Philip E. Thorpe's work include Toxin Mechanisms and Immunotoxins (47 papers), Angiogenesis and VEGF in Cancer (32 papers) and Transgenic Plants and Applications (32 papers). Philip E. Thorpe is often cited by papers focused on Toxin Mechanisms and Immunotoxins (47 papers), Angiogenesis and VEGF in Cancer (32 papers) and Transgenic Plants and Applications (32 papers). Philip E. Thorpe collaborates with scholars based in United States, United Kingdom and Germany. Philip E. Thorpe's co-authors include Sophia Ran, Rolf A. Brekken, Xianming Huang, Gabriele Bergers, Douglas Hanahan, Zena Werb, Takeshi Itoh, Gerald McMahon, Thiennu H. Vu and Kazuhiko Tamaki and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Philip E. Thorpe

132 papers receiving 10.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis

2000 2.2k citations Gabriele Bergers, Rolf A. Brekken et al. Nature Cell Biology profile →

Peers

Countries citing papers authored by Philip E. Thorpe

Since Specialization

Citations

This map shows the geographic impact of Philip E. Thorpe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip E. Thorpe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip E. Thorpe more than expected).

Fields of papers citing papers by Philip E. Thorpe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip E. Thorpe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip E. Thorpe. The network helps show where Philip E. Thorpe may publish in the future.

Co-authorship network of co-authors of Philip E. Thorpe

This figure shows the co-authorship network connecting the top 25 collaborators of Philip E. Thorpe. A scholar is included among the top collaborators of Philip E. Thorpe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip E. Thorpe. Philip E. Thorpe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Protective Effect of Anti-Phosphatidylserine Antibody in a Guinea Pig Model of Advanced Hemorrhagic Arenavirus Infection 2017 ·The Open Microbiology Journal ·John Thomas, Philip E. Thorpe	5
2	Phosphatidylserine-Targeting Antibody Induces M1 Macrophage Polarization and Promotes Myeloid-Derived Suppressor Cell Differentiation 2013 ·Cancer Immunology Research ·Yi Yin, Xianming Huang, Kristi D. Lynn, Philip E. Thorpe	128
3	Highly Specific PET Imaging of Prostate Tumors in Mice with an Iodine-124-Labeled Antibody Fragment That Targets Phosphatidylserine 2013 ·PLoS ONE ·Jason H. Stafford, Guiyang Hao, (unknown), Xiankai Sun, Philip E. Thorpe	21
4	Increased Exposure of Phosphatidylethanolamine on the Surface of Tumor Vascular Endothelium 2011 ·Neoplasia ·Jason H. Stafford, Philip E. Thorpe	139
5	Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors 2010 ·Breast Cancer Research and Treatment ·Yayun Liang, Cynthia Besch‐Williford, (unknown), Philip E. Thorpe, Salman M. Hyder	23
6	Strategies for labeling proteins with PARACEST agents 2010 ·Bioorganic & Medicinal Chemistry ·Olga Vasalatiy, Piyu Zhao, Mark Woods, (unknown), (unknown), Philip E. Thorpe, Garry E. Kiefer, A. Dean Sherry	4
7	Abstract #5463: Fully human anti-phosphatidylserine antibody inhibits the growth of prostate cancer in mice 2009 ·Cancer Research ·Yi Yin, (unknown), Philip E. Thorpe	1
8	Coincident exposure of phosphatidylethanolamine and anionic phospholipids on the surface of irradiated cells 2008 ·Biochimica et Biophysica Acta (BBA) - Biomembranes ·(unknown), Philip E. Thorpe	47
9	ANTIBODY-MEDIATED TARGETING OF “INSIDE-OUT” ANIONIC PHOSPHOLIPIDS IN VIRAL DISEASE (47.21) 2007 ·The Journal of Immunology ·(unknown), (unknown), (unknown), Philip E. Thorpe	1
10	Inhibition of Prostate Tumor Growth and Bone Remodeling by the Vascular Targeting Agent VEGF121/rGel 2006 ·Cancer Research ·Khalid A. Mohamedali, Ann T. Poblenz, Charles R. Sikes, Nora M. Navone, Philip E. Thorpe, Bryant G. Darnay, Michael G. Rosenblum	25
11	Plasma Protein β-2-Glycoprotein 1 Mediates Interaction between the Anti-tumor Monoclonal Antibody 3G4 and Anionic Phospholipids on Endothelial Cells 2006 ·Journal of Biological Chemistry ·Troy A. Luster, Jin He, Xianming Huang, Sourindra N. Maiti, Alan J. Schroit, Philip G. de Groot, Philip E. Thorpe	57
12	The Vascular-Targeting Fusion Toxin VEGF121/rGel Inhibits the Growth of Orthotopic Human Bladder Carcinoma Tumors 2005 ·Neoplasia ·Khalid A. Mohamedali, Daniel Kedar, Paul Sweeney, Ashish M. Kamat, Darren W. Davis, Beryl Y. Eve, Samuel Huang, Philip E. Thorpe, Colin P. Dinney, Michael G. Rosenblum	30
13	Anti-tumor effects of duramycin-IgG conjugate 2004 ·Cancer Research ·Jin He, Philip E. Thorpe	3
14	The angiogenic pathway ?vascular endothelial growth factor/flk-1(KDR)-receptor? in rheumatoid arthritis and osteoarthritis 2001 ·The Journal of Pathology ·Alexandra Giatromanolaki, Efthimios Sivridis, (unknown), (unknown), Philip E. Thorpe, Rolf A. Brekken, (unknown), Adrian L. Harris, (unknown), Michael I. Koukourakis	81
15	Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis breakdown → 2000 ·Nature Cell Biology ·Gabriele Bergers, Rolf A. Brekken, Gerald McMahon, Thiennu H. Vu, Takeshi Itoh, Kazuhiko Tamaki, Kazuhiko Tanzawa, Philip E. Thorpe, Shigeyoshi Itohara, Zena Werb, Douglas Hanahan	2218
16	Heparin-steroid conjugates lacking glucocorticoid or mineralocorticoid activities inhibit the proliferation of vascular endothelial cells 1996 ·Biochimica et Biophysica Acta (BBA) - Molecular Cell Research ·(unknown), (unknown), Shuzhen Li, (unknown), (unknown), Philip E. Thorpe	10
17	Antibody-directed targeting of the vasculature of solid tumors 1995 ·Breast Cancer Research and Treatment ·Philip E. Thorpe, Francis Burrows	98
18	Immunotoxins: magic bullets or misguided missiles? 1993 ·Immunology Today ·Ellen S. Vitetta, Philip E. Thorpe, Jonathan W. Uhr	170
19	Ricin B chain-containing immunotoxins prepared with heat-denatured B chain lacking galactose-binding ability potentiate the cytotoxicity of a cell-reactive ricin A chain immunotoxin 1988 ·Biochimica et Biophysica Acta (BBA) - Molecular Cell Research ·Edward J. Wawrzynczak, Alex F. Drake, Graham J. Watson, Philip E. Thorpe, Ellen S. Vitetta	14
20	Immunotoxins Containing Ricin A Or B Chains with Modified Carbohydrate Residues Act Synergistically in Killing Neoplastic B Cells In Vitro * 1985 ·PubMed ·Ellen S. Vitetta, Philip E. Thorpe	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact